- Joined
- Sep 2, 2024
- Messages
- 483
- Reaction score
- 1,166
Heard of Metsera? I hadn't heard of it. Today an article came out entitled "Metsera's Once Monthly GLP-1 Shot Looking Better than Zepbound in Early Trials."
I also saw this: Metsera isn’t putting all its eggs in one basket. The company is also advancing MET-233i, an ultra-long-acting injectable amylin analog designed for combination therapy with MET-097i.